Business Wire

MA-ACCESS-ADVANCE

9.3.2022 01:02:11 CET | Business Wire | Press release

Share
Access Advance Addresses Düsseldorf Court Ruling, Announces Revised Duplicate Royalty Policy for the HEVC Advance Patent Pool

Access Advance, an independent licensing administrator, today announced that the licensors to its HEVC Advance Patent Pool approved a revised Duplicate Royalty Policy. The revised Policy responds to the Düsseldorf District Court’s December 21, 2021 ruling, which declined to grant an injunction despite finding Vestel Germany GmbH (“Vestel”) liable for damages arising from its infringement of certain HEVC standard essential patents asserted by HEVC Advance licensors.

While Access Advance’s Duplicate Royalty Policy followed (and exceeded) long-standing industry practice, because of the substantial number of overlapping patents in the HEVC Advance Patent Pool and MPEG LA's HEVC patent pool to which Vestel was licensed (as a result of Vestel taking an MPEG LA license in 2018 before a large number of licensors left MPEG LA), the German court found such practice not FRAND. In particular, the court found such practice (1) did not impose on the HEVC Advance Patent Pool a direct legal obligation to Vestel ensuring that a licensor whose patents were licensed in both pools did not receive a duplicate royalty payment, and (2) did not adequately specify to Vestel prior to license execution the methodology each licensor would apply to prevent receipt of such duplicate royalties by licensors.

Importantly, the court once again did not express concerns with any other facet of the HEVC Advance Patent Pool, including its royalty rates. In an earlier set of patent infringement cases brought by several HEVC Advance Patent Pool licensors against MAS Elektronik, this same court expressly confirmed that the HEVC Advance pool license and rates were FRAND. Nothing about the court’s Vestel decision changes or undermines this prior and fundamental finding.

The revised Policy announced today not only resolves the issues identified by the court, but goes a significant step further in allowing licensees under both the HEVC Advance Patent Pool and another HEVC patent pool or joint licensing program that qualify to elect to receive a deduction from the HEVC Advance Patent Pool for the amount of duplicate royalties that would be received by HEVC Advance licensors on account of patents licensed under both the HEVC Advance Patent Pool and the other HEVC patent pool or joint licensing program. Previously, each HEVC Advance licensor could determine from which pool or program a licensee would receive a duplicate royalty deduction.

Details of the revised Duplicate Royalty Policy and the related Duplicate Royalty Adjustment Amendment to the HEVC Advance Patent Portfolio License and Duplicate Royalty Estimate Request can be found at: https://accessadvance.com/licensing-programs/hevc-advance/ .

About Access Advance:

Access Advance LLC (formerly HEVC Advance LLC) is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important standards-based video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Access Advance currently manages and administers the HEVC Advance Patent Pool for licensing patents essential to H.265/HEVC technology, and the separate and independent VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. For more information about Access Advance, the HEVC Advance Patent Pool, or the VVC Advance Patent Pool, please visit www.accessadvance.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye